In short
Bictegravir is a novel antiretroviral medication being studied in clinical trials for the treatment of HIV-1 infection. As part of a single-tablet regimen combined with emtricitabine and tenofovir alafenamide (B/F/TAF), bictegravir shows promise in providing effective, well-tolerated treatment for diverse populations of people living with HIV. This article summarizes key findings from recent clinical trials evaluating bictegravir-based regimens.
At a glance
- Drug Formulation
- Single-tablet regimen containing bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF)
- Populations Studied
- Treatment-naive and experienced adults, patients with renal impairment, active substance users, Hispanic/Latinx patients with advanced HIV
- Key Efficacy Measures
- Viral suppression (HIV RNA <50 copies/mL), CD4 cell recovery, time to viral suppression
- Safety Assessments
- Adverse events, laboratory abnormalities, renal function changes
- Potential Advantages
- High barrier to resistance, few drug-drug interactions, efficacy in some pre-existing resistance, single-tablet convenience
- Special Populations
- Studies in patients with renal impairment, active substance use, and advanced HIV
- Comparative Studies
- Evaluations against other antiretroviral regimens, including multi-tablet regimens
What is Bictegravir?
Bictegravir is a medication used to treat HIV-1 infection in adults. It belongs to a class of drugs called integrase strand transfer inhibitors (INSTIs), which work by blocking an enzyme that HIV needs to multiply. Bictegravir is often referred to by its brand name Biktarvy, which is a combination pill that includes two other HIV medications: emtricitabine and tenofovir alafenamide.
How Bictegravir Works
Bictegravir works by preventing HIV from inserting its genetic material into human cells. This stops the virus from making copies of itself and spreading throughout the body. By doing this, bictegravir helps to lower the amount of HIV in the blood (known as viral load) and increase the number of CD4 cells, which are important immune cells that help fight infections.
Conditions Treated with Bictegravir
Bictegravir is primarily used to treat HIV-1 infection in adults. It can be used in different situations:
- For people who are starting HIV treatment for the first time (treatment-naive)
- For people who are already on HIV treatment but want to switch to a new regimen (treatment-experienced)
- In people with advanced HIV disease (low CD4 count or AIDS-defining illnesses)
- For HIV prevention after potential exposure to the virus (post-exposure prophylaxis or PEP)
Bictegravir Formulations
Bictegravir is most commonly available as part of a combination pill called Biktarvy. This single tablet contains:
- Bictegravir 50 mg
- Emtricitabine 200 mg
- Tenofovir alafenamide 25 mg
This combination allows patients to take just one pill once a day, which can make it easier to stick to the treatment regimen.
Effectiveness of Bictegravir
Clinical trials have shown that bictegravir-based regimens are highly effective in treating HIV. Some key findings include:
- High rates of viral suppression (HIV RNA less than 50 copies/mL) at 24 and 48 weeks of treatment
- Effectiveness in both treatment-naive and treatment-experienced patients
- Potential for rapid start of treatment in newly diagnosed patients, including those with advanced HIV
Safety and Side Effects
Bictegravir is generally well-tolerated, but like all medications, it can cause side effects. Common side effects may include:
- Diarrhea
- Nausea
- Headache
- Fatigue
- Abnormal dreams
Most side effects are mild and tend to improve over time. Serious side effects are rare but can occur. Your healthcare provider will monitor you for any potential issues.
Use in Special Populations
Bictegravir has been studied in various populations, including:
- People with kidney problems: Bictegravir/emtricitabine/tenofovir alafenamide may be safer for the kidneys compared to older HIV medications
- People who use illicit substances: Studies are ongoing to evaluate the effectiveness of bictegravir in this population
- Marginalized populations: Research is being conducted to assess the benefits of switching to bictegravir-based regimens in underserved communities
Drug Interactions
Bictegravir has fewer drug interactions compared to some older HIV medications. However, it's important to tell your healthcare provider about all medications, supplements, and herbal products you use. Some medications that may interact with bictegravir include:
- Certain medications for tuberculosis
- Some seizure medications
- Antacids and iron supplements (these should be taken at different times than bictegravir)
Switching to a bictegravir-based regimen may reduce the number of drug interactions for some patients.
Ongoing Research
Research on bictegravir is ongoing, with studies looking at:
- Long-term effectiveness and safety
- Use in specific populations, such as people who use illicit substances
- Impact on quality of life and sleep
- Effects on the gut microbiome
These studies will help to further understand the benefits and potential risks of bictegravir-based HIV treatment.